Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 B-cell inhibitors as therapy for rheumatoid arthritis: an update.

Literature DB >> 17915096

B-cell inhibitors as therapy for rheumatoid arthritis: an update.

Abstract

A revolution in the treatment of rheumatoid arthritis has occurred in recent years. This holds particularly true for B-cell-directed therapies for rheumatoid arthritis. The approval of rituximab for the treatment of rheumatoid arthritis has not only expanded the armamentarium of therapies for rheumatologists, but it has also led the way to better understanding of the biologic sequelae of these treatments as well as the potential to better understand the etiology of autoimmune diseases. This review updates the latest B-cell therapies in rheumatoid arthritis.

Entities: Chemical Disease

Mesh：

Substances：

Year: 2007 PMID： 17915096 DOI： 10.1007/s11926-007-0064-4

Source DB: PubMed Journal: Curr Rheumatol Rep ISSN： 1523-3774 Impact factor: 4.592

24 in total

Review 1. B cells move to centre stage: novel opportunities for autoimmune disease treatment.

Authors: Jeffrey L Browning
Journal: Nat Rev Drug Discov Date: 2006-07 Impact factor: 84.694

2. Bone marrow B-lineage cells in patients with rheumatoid arthritis following rituximab therapy.

Authors: M J Leandro; N Cooper; G Cambridge; M R Ehrenstein; J C W Edwards
Journal: Rheumatology (Oxford) Date: 2006-05-30 Impact factor: 7.580

3. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial.

Authors: Paul Emery; Roy Fleischmann; Anna Filipowicz-Sosnowska; Joy Schechtman; Leszek Szczepanski; Arthur Kavanaugh; Artur J Racewicz; Ronald F van Vollenhoven; Nicole F Li; Sunil Agarwal; Eva W Hessey; Timothy M Shaw
Journal: Arthritis Rheum Date: 2006-05

4. Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production.

Authors: Frédéric Lavie; Corinne Miceli-Richard; Marc Ittah; Jérémie Sellam; Jacques-Eric Gottenberg; Xavier Mariette
Journal: Ann Rheum Dis Date: 2006-10-13 Impact factor: 19.103

5. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse.

Authors: Geraldine Cambridge; William Stohl; Maria J Leandro; Thi-Sau Migone; David M Hilbert; Jonathan C W Edwards
Journal: Arthritis Rheum Date: 2006-03

6. Rituximab: an insider's historical perspective.

Authors: A J Grillo-López
Journal: Semin Oncol Date: 2000-12 Impact factor: 4.929

7. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis.

Authors: Petra Roll; Arumugam Palanichamy; Christian Kneitz; Thomas Dorner; Hans-Peter Tony
Journal: Arthritis Rheum Date: 2006-08

8. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.

Authors: Jonathan C W Edwards; Leszek Szczepanski; Jacek Szechinski; Anna Filipowicz-Sosnowska; Paul Emery; David R Close; Randall M Stevens; Tim Shaw
Journal: N Engl J Med Date: 2004-06-17 Impact factor: 91.245

9. Mice carrying a CD20 gene disruption.

Authors: T L O'Keefe; G T Williams; S L Davies; M S Neuberger
Journal: Immunogenetics Date: 1998-07 Impact factor: 2.846

Review 10. Roles of B cells in rheumatoid arthritis.

Authors: Gregg J Silverman; Dennis A Carson
Journal: Arthritis Res Ther Date: 2003-12-02 Impact factor: 5.156

5 in total

Review 1. Graves' ophthalmopathy.

Authors: Rebecca S Bahn
Journal: N Engl J Med Date: 2010-02-25 Impact factor: 91.245